24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review

Abstract Background Buprenorphine (Bup) is a first-line medication for opioid use disorder (OUD) that carries risk of precipitated withdrawal (PW) with ongoing need for rapid and effective initiation strategies. We report a novel approach to low-dose initiation using transdermal Bup patches (TD-Bup)...

Полное описание

Библиографические подробности

Главные авторы:	Pouya Azar, Victor W. Li, Mohammadali Nikoo, Jennifer LaBranche, James S. H. Wong, Jessica Machado, Tam To, Alaa Al Hawamdeh, Martha J. Ignaszewski, Andrew A. Herring, Marc Vogel, Laura Kehoe, Amer Raheemullah, Ruchi Fitzgerald, Reinhard M. Krausz, Julio S. G. Montaner, Anil R. Maharaj
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2026-03-01
Серии:	Addiction Science & Clinical Practice
Предметы:	Opioid use disorder Fentanyl Buprenorphine Transdermal Initiation Buprenorphine extended-release
Online-ссылка:	https://doi.org/10.1186/s13722-026-00657-3
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!